Amycretin is a dual oral agonist of GLP-1 and amylin receptors. GLP-1 is by now a widely known target which semaglutide is ...

The highly anticipated new obesity pill shows the potential for greater and faster weight loss than Wegovy. There is a new ...

Ozempic maker Novo Nordisk (NVO) shared more details about its experimental anti-obesity pill — that seems to be more ...

Novo Nordisk said on Wednesday its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for ...

Novo Nordisk reported that its new obesity pill led to substantial weight loss in an early study, boosting the company’s ...

Novo Nordisk has lifted the lid on a phase 1 trial of its oral amylin and GLP-1 receptor co-agonist, linking the candidate to ...

Share on Pinterest Novo Nordisk’s new weight loss pill, amycretin, has had promising results in an early clinical trial. Image credit: SERGEI GAPON/Getty Images. Amycretin, a new weight loss ...

Novo Nordisk presented data on its next-generation weight-loss candidate, amycretin, which showed a significant 13% weight ...

NVO stock gains 4.2% after it presents efficacy data superior to Wegovy for its new oral pill, amycretin, in an early-stage ...

The first-in-human study has found that participants who received 50mg amycretin reduced their body weight by 10.4 per cent ...

Data from an early stage clinical trial suggests Novo Nordisk’s new weight loss pill amycretin could produce greater and more ...

Amycretin’s phase 1 trials show study participants ... stiff competition for Eli Lilly and a sign to investors that Novo Nordisk might have a pipeline of next-generation drugs.